Rexahn Pharmaceuticals Inc. is a publicly traded clinical stage pharmaceutical company dedicated to commercializing first-in-class and best-in-class therapeutics for cancer and central nervous system (CNS) disorders. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™—all potential best-in-class therapeutics. Rexahn also operates key R&D programs of nanomedicines, 3D-GOLD and TIMES drug discovery platforms.